PPU review
PPU
DISEASE
Site investigators requested unblinding of treatment allocation for 86/152 (57%) participants prior to the initial analysis cutoff date: 50 assigned regorafenib and 36 assigned placebo. Globally, the PPU review found evidence to support progressive disease having been documented prior to requesting PPU in 82/86 (95%) of cases (Table PPU review